The devices are approved for the treatment of occlusive disease in native superficial femoral arteries and proximal popliteal arteries, and are marketed by the Bard peripheral vascular division, located in Tempe, Arizona.
Timothy Ring, chairman and CEO of Bard, said: “The approval of the LifeStent vascular stent positions Bard as the only company offering a stent indicated for the treatment of SFA and proximal popliteal disease in the US. It’s also the third pre-market approval we have received for a peripheral vascular stent or stent-graft in the last five months.
“This demonstrates our ability to execute rigorous clinical trials and our commitment to introducing innovative products to address the needs of clinicians and their patients.”